At a recent conference, executives from across the industry shared their thoughts on how the healthcare sector can ensure its use of AI is ethical and responsible. They highlighted the need for collaboration, trust building and pragmatic thinking.
This year's HIMSS conference featured a variety of news announcements — from acquisitions to new product launches to advanced partnerships. In this list, MedCity News compiled short summaries for six of the conference's most notable announcements.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
At HIMSS, Philips and AWS announced that they are expanding their collaboration with the goal of scaling digitized pathology slides in the cloud. The partners seek to help pathology labs better store and analyze vast volumes of data, as well as adopt more streamlined, cloud-based workflows to reduce clinician burnout.
Two of Philips' most notable RSNA announcements were that its new cloud-based PACS is available and that its helium-free mobile MRI system will soon be deployed. More than 80 sites across the U.S. and Latin America have already migrated to Philips' new PACS, and its mobile MRI system will be traveling to various cities next year.
The digital pathology market is poised for rapid growth in the U.S., with several vendors vying for dominance. The imaging management systems made by Leica Biosystems and Philips seem to be leading the pack in this competitive market, according to a new report.
The FDA granted 510(k) clearance to two of Philips’ newest acute care patients monitors, the IntelliVue MX750 and MX850. A year ago, the company had gotten an emergency use authorization for its monitors.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Paris-based Cardiologs has a software platform to screen for arrhythmias from ECG data. It would add to Philips' portfolio of cardiac software for hospitals and remote monitoring.
The reimbursement model for remote patient monitoring needs to evolve as it may be holding providers back from investing in these programs, according to panelists at the MedCity INVEST Digital Health conference. Key issues with the structure as it stands now include the fact that there are too many gray areas that result in claims denials.
The health technology company will use the investment to deploy its cancer care management platform and remote monitoring program at more health systems and to advance its research capabilities. Philips Health Technology Ventures led the equity round, and Cerner was a returning investor.
AI tools increasingly occupy a regulatory gray area in healthcare. For clinicians to assess whether they are trustworthy, they need transparency on how they work, said panelists at CES.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Remote monitoring startup BioIntelliSense and Royal Phillips received $2.8 million to test BioIntelliSense’s device for the early detection of Covid-19 symptoms. The startup received FDA clearance for its small, adhesive monitoring device last year.
Designed long before the Covid-19 pandemic, Philips received FDA clearance for a wearable sensor that can track respiratory rate. The disposable patch is used to monitor patients after they are moved from the ICU to another care setting.
The Consumer Technology Association brought together more than 50 companies in healthcare and technology to create a standard for the use of AI in healthcare. CTA said the goal was to create definitions for murky terms, and help healthcare companies improve data integrity and create more trustworthy solutions.
The two healthcare companies will provide remote monitoring for Medicare Advantage members at high risk of hospital readmission and congestive heart failure patients.
The company's platform uses automated text messages and emails to help get patients to their appointments, guide patients in their pre and post-op care and provide additional educational health information.